Overview
Individuals with type 2 diabetes (T2DM) have among the highest risk of developing dementia in their lifetimes in some study cohorts. Currently we do not know with certainty which molecular pathways underlie the increased risk of future Alzheimer’s disease (AD) and dementia among diabetics and if these same molecular pathways are also shared among elderly individuals in the earliest stages of AD. The aim of the Lipoproteins in AD and diabetes (LADD) study is to evaluate if poor glycemic control and related changes to peripheral Apolipoprotein A1 (ApoA1) is a significant factor in central nervous system inflammation as well as vascular, neuronal, and synaptic changes related to poor cognition in T2DM and those individuals at the preclinical stages of AD. The LADD study will collect detailed data and model the key players important in cognitive outcomes (Apolipoproteins, metabolic syndrome changes, cardiovascular disease, inflammation, neuronal, and AD related brain changes) among 70 adults with T2DM and 120 individuals at high risk of AD. This is critical information to determine how to best target T2DM management to improve cognitive outcomes among those most vulnerable to cognitive decline and to enable targeting of new therapeutic interventions to prevent future cognitive deterioration in future well powered interventional clinical trials in T2DM and preclinical AD.
Contact Information:
Jagan A Pillai MD PhD
pillaij@ccf.org
Funding Sources:
Department of Defense W81XWH-22-1-0335
Apolipoprotein A1 Modifications Related to Cognitive Decline in Type 2 Diabetes and Preclinical Alzheimer's Disease
Members and Collaborations
Cleveland Clinic
- Lynn Bekris, PhD
- Sangeeta Kashyap MD
- James Leverenz, MD
- Mark Lowe, PhD
- Kunio Nakamura PhD
- Stephen Rao PhD
- Wanyong Shin PhD
External Relationships and Collaborations
- Takhar Kasumov, PhD, Northeast Ohio Medical University
